Biased G_s Versus G_q Proteins and β -Arrestin Signaling in the NK1 Receptor Determined by Interactions in the Water Hydrogen Bond Network^{*}

Received for publication, February 2, 2015, and in revised form, August 11, 2015 Published, JBC Papers in Press, August 12, 2015, DOI 10.1074/jbc.M115.641944

Louise Valentin-Hansen^{+§1}, Thomas M. Frimurer[¶], Jacek Mokrosinski^{+§}, Nicholas D. Holliday^{||2}, and Thue W. Schwartz^{+§3}

From the [‡]Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, The Panum Institute, [§]Novo Nordisk Foundation Center for Basic Metabolic Research, and [¶]Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark and the [∥]Cell Signaling Research Group, School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, United Kingdom

Background: A unique Glu(2.50) in the NK1 receptor interacts directly with Ser(3.39) and Asn(7.49). **Results:** Mutational changes in this interface create receptors that selectively signal through G_q or β -arrestin *versus* G_s . **Conclusion:** A focal point in differentiation between G_s , G_q , and β -arrestin signaling was identified. **Significance:** This network constitutes an allosteric interface essential for 7TM receptor fine-tuning toward different signaling pathways.

X-ray structures, molecular dynamics simulations, and mutational analysis have previously indicated that an extended water hydrogen bond network between trans-membranes I-III, VI, and VII constitutes an allosteric interface essential for stabilizing different active and inactive helical constellations during the seven-trans-membrane receptor activation. The neurokinin-1 receptor signals efficiently through G_{q} , G_{s} , and β -arrestin when stimulated by substance P, but it lacks any sign of constitutive activity. In the water hydrogen bond network the neurokinin-1 has a unique Glu residue instead of the highly conserved AspII:10 (2.50). Here, we find that this GluII:10 occupies the space of a putative allosteric modulating Na⁺ ion and makes direct inter-helical interactions in particular with SerIII:15 (3.39) and AsnVII:16 (7.49) of the NPXXY motif. Mutational changes in the interface between GluII:10 and AsnVII:16 created receptors that selectively signaled through the following: 1) G_q only; 2) β -arrestin only; and 3) G_q and β -arrestin but not through G_s. Interestingly, increased constitutive G_s but not G_q signaling was observed by Ala substitution of four out of the six core polar residues of the network, in particular SerIII:15. Three residues were essential for all three signaling pathways, *i.e.* the water-gating micro-switch residues TrpVI:13 (6.48) of the CWXP motif and TyrVII:20 (7.53) of the NPXXY motif plus the totally conserved AsnI:18 (1.50) stabilizing the kink in trans-membrane VII. It is concluded that the interface between position II:10 (2.50), III:15 (3.39), and VII:16 (7.49) in the center of the water hydrogen bond network constitutes a focal point for fine-tuning seven trans-

membrane receptor conformations activating different signal transduction pathways.

Within the last decade, high resolution x-ray structures of a large number of family A seven trans-membrane (7TM),⁴ G protein-coupled receptors have underlined the association between highly conserved residues in the trans-membrane segments and receptor function (1-4). These conserved residues are particularly located in the intracellular parts of the transmembrane helices where they function either as microswitches or are involved in the large water-mediated hydrogen bond network. This network constitutes an extended allosteric interface between the helices that perform the large scale movements when the receptor alternates between inactive and active conformations (2, 5). The water-mediated hydrogen bond network is limited at the extracellular side by TrpVI:13 (6.48)⁵ of the so-called CWXP motif in the middle of TM-VI, which forms the "gate" between the network and the extracellular facing ligand-binding pocket (2). At the cytoplasmic side, the network is limited by TyrVII:20 (7.53), which is part of the NPXXY motif at the intracellular end of TM-VII (Fig. 1A). Previously, by use of molecular dynamics simulations and molecular pharmacological means, we have presented evidence indicating that key polar residues of this interface are essential for the signal transduction process in the β 2-adrenergic receptor (B2AR) and that TrpVI:13 (6.48) and TyrVII:20 (7.53) appear to function as gates for the movements of water molecules in and out of the network (5).



^{*} The authors declare that they have no conflicts of interest with the contents of this article.

¹ Recipient of a Ph.D. scholarship from the Faculty of Health Sciences at University of Copenhagen.

² Supported by funding from the Medical Research Council United Kingdom Grant G0700049.

³ To whom correspondence should be addressed: Laboratory for Molecular Pharmacology, Panum Institute, University of Copenhagen, Blegdamsvej 3, Copenhagen DK-2200, Denmark. Tel.: 45-2262-2225; Fax: 45-3532-7610; E-mail: tws@sund.ku.dk.

⁴ The abbreviations used are: 7TM, 7-trans-membrane; TM, trans-membrane; B2AR, β2-adrenergic receptor; A_{2A}AR, adenosine A_{2A} receptor; NK1, neurokinin-1; PDB, Protein Data Bank; IP₃, inositol 1,4,5-trisphosphate; SP, substance P.

⁵ The Schwartz/Baldwin generic numbering system for 7TM receptors, which is based on the actual location of the residues in each trans-membrane helix, is used throughout the article (41).

The polar residues of the water hydrogen bond network are not only highly conserved in the primary structure (Fig. 1D) but are also almost superimposable in all of the other 20 unique inactive x-ray structures (Fig. 1A) solved to date (6-26). Surprisingly, the structures revealed that in the inactive state almost no hydrogen bonds are observed between the polar residues themselves. Instead, they interact through a number of structural water molecules generating the extended hydrogen bond network as shown for the inactive adenosine A_{2A} receptor $(A_{2A}AR)$ and B2AR structures in Fig. 1, A-C (10, 16). Interestingly, a sodium ion was identified as an important part of this network located almost identically in the A_{2A}AR, the proteaseactivated receptor 1, and most recently in the 1.8-Å high resolution structure of the δ -opioid receptor (12, 26–28). In these structures, the sodium ion is coordinated by the highly conserved AspII:10 (2.50) in TM-II, SerIII:15 (3.39) in TM-III and nearby water molecules in a position previously shown to be taken up by either structural water molecules or left as a relatively large "empty space" in x-ray structures of inactive forms of other 7TM receptors (28). Importantly, in the active structure of the B2AR and the active-like structures of the $A_{2A}AR$, this region has undergone major conformational changes, including the well recognized major tilts of the intracellular parts of TM-V (inward) and TM-VI (outward) combined with an inward tilt of TM-VII (more than 2 Å combined with rotation), and an axial shift of TM-III (29, 30). These movements eliminate much of the space occupied by water and the sodium ion in the inactive conformation so that in the active state the polar residues instead mainly make hydrogen bonds directly with each other (Fig. 1C). The notion that a sodium ion stabilizes the inactive conformation of 7TM receptors, and acts as negative allosteric modulators, was well established 11/2 decades ago through studies of the α 2A adrenergic receptor, the A_{2A}AR, the μ - and δ -opioid receptors, and the D2 dopamine receptor, for example (31–37). However, we now have structural proof of this interaction in the $A_{2A}AR$ and the $\delta\text{-opioid}$ receptor, which provides a detailed picture of how other residues besides AspII:10 (2.50) (in particular SerIII:15 (3.39)) are also involved in the binding of the allosteric negative regulator Na⁺ (16, 27, 30).

In this study, we investigate the relative role of different residues in the conserved polar interface in the neurokinin-1 (NK1) receptor, which is activated by substance P and signals through both the G_{g} and the G_{s} pathway (38-41). A unique structural feature of the NK1 receptor is a glutamic acid residue in position II:10 (2.50), in contrast to aspartic acid found in more than 98% of other family A receptors (42). Interestingly, the unstimulated NK1 receptor is very "silent" with no evidence of constitutive activity resulting from spontaneous transition to the active state. For more than 2 decades we have performed structural-functional studies on the NK1 receptor and have never observed measurable constitutive activity, and in contrast to most other 7TM receptors, we have never identified an NK1 mutant showing ligand-independent signaling (38, 43-47). This is particularly surprising as it is generally known in the field that it is rather easy to find mutations in 7TM receptors that make them signal with high constitutive activity.

We now find that in molecular models of the NK1 receptor the γ -carboxylic acid group of the larger GluII:10 (2.50) side chain (compared with Asp) is located at or very close to the position where the negative allosteric modulating sodium ion is found in the A_{2A}AR, the δ -opioid receptor, and the β 1-adrenergic receptor, for example (27, 28, 32, 48), and that it makes direct hydrogen bonds to other members of the water-hydrogen bond network, SerIII:15 (3.39), and AsnVII:16 (7.49). Mutational analysis indicates that GluII:10 and its two hydrogen bond partners in different ways are involved in tuning G_s versus G_q and β -arrestin signaling and that negative modulatory Na⁺ effects could be induced in the NK1 receptor by "reintroducing" Asp in position II:10.

Experimental Procedures

Comparative Homology Modeling-The sequence of the human NK1 receptor was obtained at the Uniprot web page. The distinct x-ray structures (available at the time the modelings were conducted) of 7TM receptors in inactive-like states (adenosine A_{2A} (PDB code 4EIY), β 1-adrenergic receptor (PDB code 2VT4), β2-adrenergic receptor (PDB code 2RH1), chemokine CXCR4 (PDB code 3ODU), chemokine CCR5 (PDB code 4MBS), dopamine D3 (PDB code 3PBL), histamine H1 (PDB code 3RZE), muscarinic M2 (PDB code 3OUN), muscarinic M3 (PDB code 4DAJ), serotonin $5HT_{1B}$ (PDB code 4IAR), serotonin 5HT_{2B} (PDB code 4IB4), μ -opioid (PDB code 4DKL), δ-opioid (PDB code 4EJ4), κ-opioid (PDB code 4DJH), nociceptin (PDB code 4EA3), protease-activated receptor 1 (PDB code 3VW7), sphingosine S1P (PDB code 3V2Y), and rhodopsin (PDB code 1GZM)) as well as the structures in active-like states (adenosine A_{2A} (PDB code 3QAK), β 2-adrenergic receptor (PDB code 3SN6), muscarinic M2 (PDB code 4MQS), neurotensin 1 receptor (PDB code 4GRV)) were obtained from the PDB database. The structures were superimposed with respect to the intracellular half of TM-I-III and -VII using the CEAlign protocol in PyMOL. Pairwise sequence alignments and comparative homology models (excluding intra- and extracellular loops) of the NK1 receptor were produced in ICM 3.7b using the inactive- and active-like structures of A2AR and B2AR as templates that devised reasonable high sequence identity to the intracellular half of TM-I-III and -VII. GluII:10 was assumed to be negatively charged as it is located in-between SerIII:15 and ThrVII:13 in an optimal position to be involved in hydrogen bond interactions, the hydroxyl side chain of SerIII:15, and the co-existence of "conserved" bulky water molecules observed in other receptors with similar environments. Initially, hydrogen atoms and side chains were optimized using the comparative modeling protocol in ICM. When modeling the inactive state of NK1R, the sodium ion and structural water molecules of the template structures were "copied" to the comparative NK1 receptor models. The location of the sodium ion and water molecules was initially accessed in the presence of a fixed NK1 receptor model. The sodium ion and a nearby water molecule, which are involved in hydrogen bond interactions with AspII:10 and SerIII:15 in the parent A2A AR and B2AR structures, were removed from the NK1 receptor models as they make steric clashes with the larger (compared with Asp) carboxyl acid side chain of GluII:10 in the NK1 receptor models.

Local optimization of side chains within 8 Å of this co-localized sodium ion/water molecule was unable to release the strain when optimizing all atoms using the biased probability Monte Carlo optimization protocol (200 global moves and 100 local minimization calls). To ensure acceptance of the remaining water molecules, side chains and water molecules were globally optimized using the Monte Carlo conformational sampling procedure in the presence of a fixed main chain conformation in ICM 3.7b. Finally, the resulting NK1 models were minimized in 300 steps of steepest decent, using the MMFF force field, and all atoms were free to move. In this work we only present the NK1 receptor model based on $A_{2A}AR$ as the corresponding NK1 receptor model based on B2AR is highly similar.

Materials—Substance P and ghrelin were purchased from Bachem and ¹²⁵I-labeled Lys³-SP from PerkinElmer Life Sciences. Pindolol was purchased from Sigma, and AR-231453 was a generous gift from Arena Pharmaceuticals (San Diego).

Molecular Biology—The NK1, B2AR, and GHSR cDNA were cloned into the eukaryotic expression vector pCMV-Tag (2B) (Stratagene), and GPR119 cDNA was cloned into the pcDNA3.1 vector (Invitrogen). Mutations were constructed by PCR using the QuikChange method. All PCR experiments were performed using *Pfu* polymerase (Stratagene) according to the instructions of the manufacturer. All mutations were verified by DNA sequence analysis by MWG (Ebersberg, Germany). For β -arrestin recruitment, cDNAs encoding native and mutant NK1 receptors were tagged at the C terminus with an enzyme donor fragment of β -galactosidase.

Transfections and Tissue Culture—COS-7 cells were grown in Dulbecco's modified Eagle's medium 1885 supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 μ g/ml streptomycin. Cells were transfected with 20 μ g/75 cm² DNA using the calcium phosphate precipitation method with chloroquine addition as described previously (45).

CHO-K1 cells stably expressing β -arrestin2 tagged with the enzyme-accepting portion of a β -galactosidase enzyme were grown in Ham's F-12 media supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, 100 μ g/ml streptomycin, and 300 μ g/ml hygromycin. Cells were transfected using 0.15 μ l of FuGENE (Promega, Madison, WI)/well in opaque white 96-well plates using 50 ng of DNA/well according to the manufacturer's protocol.

Cell Surface Expression (ELISA)—Cells transfected and seeded for IP₃ or cAMP were in parallel seeded for ELISA. The cells were washed twice with 200 μ l of phosphate-buffered saline (PBS), fixed with 150 μ l of paraformaldehyde for 10 min, and finally incubated in blocking solution (PBS plus 3% dry milk) for 30 min at room temperature. Subsequently, the cells were incubated for 1 h at room temperature with anti-FLAG (M2) (Sigma) antibody diluted 1:1000. The cells were washed three times with PBS and incubated for 1 h at room temperature with anti-body (Sigma) diluted 1:1250. After three additional washing steps with PBS, immunoreactivity was discovered by addition of horseradish peroxidase. The absorbance was read by Top-Count (PerkinElmer Life Sciences).

Competition Binding Assay—Transfected COS-7 cells were plated in poly-D-lysine-coated 96-well plates at a density of

500–20,000 cells/well aiming at 5–10% binding of the radioactive ligand. The following day the binding experiments were performed for 3 h at 4 °C using ~25 pM ¹²⁵I-labeled SP (PerkinElmer Life Sciences). Binding assays were performed in 0.1 ml of a HEPES buffer, pH 7.4, supplemented with 1 mM CaCl₂, 5 mM MgCl₂, 0.1% (w/v) bovine serum albumin, and 40 μ g/ml bacitracin with or without increasing concentrations of NaCl. Nonspecific binding was determined as the binding in the presence of 1 μ M unlabeled SP. After two washes in cold buffer, Lysis buffer (1% SDS, 200 mM NaOH) was added for 30 min, and radioactivity was counted.

Phosphatidylinositol Turnover Assay-One day after transfection, COS-7 cells were incubated for 24 h with 5 μ Ci of myo-[³H]inositol (catalogue no. PT-271, Amersham Biosciences) in 300 μ l of medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 μ g/ml streptomycin per well. Cells were washed twice in 20 mM HEPES buffer (pH 7.4, supplemented with 140 mM NaCl, 5 mM KCl, 1 mM MgSO₄, 1 mM CaCl₂, 10 mM glucose, 0.05% (w/v) fetal bovine serum) and then incubated in 0.2 ml of HEPES buffer supplemented with 10 mM LiCl at 37 °C for 15 min. After stimulation with SP for 45 min at 37 °C, cells were extracted with 10 mM formic acid followed by incubation on ice for 30 min. The resulting supernatant was purified on AG 1-X8 anionexchange resin (Bio-Rad) to isolate the negatively charged inositol phosphates. After application of the cell extract to the column, the columns were washed twice with GPI buffer (60 mM sodium formate and 100 mM formic acid) to remove glycerophosphoinositol. Inositol phosphates were eluded by the addition of elution buffer (1 mm ammonium formate, 100 mm formic acid). Determinations were made in duplicate. The columns containing AG 1-X8 anion-exchange resin were regenerated by the addition of 3 ml of regeneration buffer (3 M ammonium formate, 100 mM formic acid) and 10 ml of water.

cAMP Assay—One day after transfection, COS-7 cells were plated into white 96-well plates (20,000 cells/well). The next day, the cAMP assay was performed using DiscoveRx HitHunterTM cAMPxs+ kit (Fremont, CA) according to the manufacturer's protocol.

 β -Arrestin2 Recruitment—The day after transfection, β -arrestin2 recruitment was determined using DiscoveRx Path-Hunter[®] β -arrestin GPCR assay (Fremont, CA) according to the manufacturers protocol.

Calculations—EC₅₀ values were determined by nonlinear regression using the Prism 6.0 software (GraphPad Software, San Diego). Unpaired *t* test (p < 0.05) was performed using the Prism 6.0 software (GraphPad software, San Diego).

Results

Modeling of the Polar Network in the NK1 Receptor—Analysis of 20 unique inactive 7TM receptor structures in complexes with inverse agonists or antagonists demonstrated that polar, water-, and sodium ion-coordinating residues of the conserved interface between the intracellular segments of TM-I–III and -VII, can be almost perfectly superimposed (Fig. 1, *A* and *B*) (7–21, 23–26, 50). This is in contrast to residues in the extracellular ligand-binding pocket, which shows larger variations in sequence and structure. Although a sodium ion has only been






FIGURE 1. **Structural conservation of the polar interface between TM-I–III and -VII.** *A*, structural distribution of conserved polar residues between the intracellular half of TM-I–III and -VII of 18 unique inactive GPCR structures. The residues AsnI:18 (1.50), AspII:10 (2.50), SerIII:15 (3.39), SerVII:12 (7.45), ThrVII:13 (7.46), and AsnVII:16 (7.49) of the conserved polar interface restricted by the functionally important and conserved TrpVI:13 (6.48) and TyrVII:20 (7.53) in the antagonist-bound structures of $A_{2a}AR$ (PDB code 4EIY solved at 1.8 Å resolution) (*blue*) and B2AR (PDB code 2RH1) (*yellow*) are shown as *sticks*. The corresponding residues in the other inactive structures are shown by *gray lines. B*, close-up view of the polar interface comprising a sodium ion (*purple sphere*) and water molecules (*red spheres*). Co-localized water molecules in the $A_{2a}AR$ and the B2AR structure are shown as *yellow spheres*. The salt bridge between sodium and AspII:10 (2.50) and water-mediated hydrogen bond interactions are shown as *gray dotted lines. C*, close-up view of the polar pocket in the active-like agonist-bound $A_{2a}AR/UK432,097$ structure (PDB code 3QAK) (*blue*) and the active agonist-bound B2AR structure in complex with G_s (PDB code 3SN6). *D*, polar pocket alignment of the distinct inactive experimental structures compared with the conforming sequence in the NK1 receptor, which have a glutamic acid instead of the highly conserved AspII:10 (2.50). *E* and *F*, structural details of AspII:10 Glu substitution). Water molecules that make steric clashes with the substituted glutamic acid are shown as big *transparent spheres*.

directly identified in this polar interface of the $A_{2A}AR$, protease-activated receptor 1, and the δ -opioid receptors, there is also clearly room for it between the highly conserved AspII:10 (2.50) and SerIII:15 (3.39) in all other inactive receptor conformations (37). In contrast, in the molecular model of the inactive conformation of the NK1 receptor, the γ -carboxyl side chain of GluII:10 replaces the sodium ion and/or one or more water molecules making direct rather than water-mediated interactions with not only SerIII:15 (3.39) but also with AsnVII:16 (7.49) (Figs. 1, *E* and *F*, and 2*A*). The helix organization and side chain packing of the energy-optimized NK1 receptor models are highly similar to the inactive experimental structures when superimposed with respect to conserved key residues in the intracellular half of TM-I–III and -VII. Either of the water molecules in the refined models deviate more than 0.75 Å from their original positions, and rotamer states of side chains involved in the water-mediated hydrogen bonds remain unchanged. In addition, GluII:10 (2.50) interacts with Tyr-VII:20 (7.53) through hydrogen bond interactions with a single water molecule, in contrast to the interaction of AspII:10 (2.50) with TyrVII:20 (7.53) in the inactive structures of $A_{2A}AR$ and B2AR, which is mediated through two water molecules (5, 10, 51).

In the models of the active conformation of the NK1 receptor built over the active structures of the B2AR- G_s and $A_{2A}AR$ receptors (16, 29), the volume of the polar interface is greatly




FIGURE 2. **NK1 receptor models**. *A*, side and top close-up view of the conserved polar interface, including Asnl:18 (1.50), Glull:10 (2.50), SerIII:15 (3.39), SerVII:12 (7.45), ThrVII:13 (7.46), and AsnVII:16 (7.49) in the inactive NK1 receptor model restricted by the functionally important and conserved residues TrpVI:13 (6.48) and TyrVII:20 (7.53). Water molecules are shown as *red spheres* and hydrogen bonds as *gray dotted lines*. In contrast to highly conserved AsplI:10, the longer GlulI:10 side chain in the NK1 model is predicted to make direct rather than water-mediated interactions with SerIII:15 and AsnVII:16. *Dashed red arrows* show the conformational rearrangements of TM-II, -III, and -VII (illustrated by *light green* and *transparent circles*) required to obtain an "active" NK1 receptor structure consistent with common conformational changes observed in distinct active structures. *B*, model of the conserved polar interface of the NK1 receptor in an active state, based on the agonist-bound A_{2A}AR structure (PDB code 3QAK).

reduced due to the inward movement of TMVII toward TMIII by more than 2 Å, which effectively "squeezes" out the possible sodium ion and most of the structural water molecules (Fig. 2, *A* and *B*). In this model, the carboxylic acid side chain of GluII:10 (2.50) could either be making direct interactions with SerII:15 (3.39), ThrVII:13 (7.46), and AsnVII:16 (7.49) or direct interactions with SerIII:15 (3.39) and AsnVII:16 (7.49) depending on the detailed side chain packing (Fig. 2*B*). In conclusion, the γ -carboxyl side chain of GluII:10 (2.50) in the NK1 receptor appears to be substituting the Na⁺ in the polar interface making direct instead of water-mediated hydrogen bond interactions to other members of the hydrogen bond network (Fig. 2*B*).

Functional Effects of Ala Substitution of the Polar Residues in the NK1 Hydrogen Bond Network—The functional importance of each residue in the water hydrogen bond network of the NK1 receptor was probed by Ala substitutions, and constitutive and SP-induced signaling were determined for the three different signal transduction pathways as follows: 1) G_q signaling monitored by IP₃ accumulation assay (Fig. 3); 2) G_s signaling monitoring by cAMP production (Fig. 4); and 3) β -arrestin mobilization measured by an enzyme complementation assay (Fig. 5). The effect of the mutations on cell surface expression was determined for each of the mutants using cell surface ELISA (Fig. 3, *insets*).

Effects of Ala Substitutions on G_q Signaling—Ala substitution of each of the two micro-switch residues TrpVI:13 (6.48) of the CWXP motif in TM-VI and TyrVII:20 (7.53) of the NPXXY motif in TM-VII, which place respective extracellular and intracellular limits on the hydrogen bond network, eliminated SP-induced signaling of the NK1 receptor through the G_q pathway as determined by IP₃ accumulation (Fig. 3, *h* and *i*, and Table 1). Ala substitution of the almost 100% conserved AsnI:18

(1.50), which in the inactive receptor structures forms a direct hydrogen bond to the backbone carbonyl group of ThrVII:13 (7.46) that is exposed at the helical kink in TM-VII (2), also eliminated SP-induced G_q signaling (Fig. 3d). Similarly, Ala substitution of GluII:10 (2.50) totally eliminated SP-induced G_a signaling (Fig. 3c). There was no indication of increased constitutive G_a signaling in the GluII:10 to Ala mutant receptor (Fig. 3c), which otherwise could have been expected based on the potential function of GluII:10 as a tethered negative allosteric regulator as discussed in the modeling section above. In TM-VII, Ala substitution of SerVII:12 (7.45) impaired the SP-induced IP_3 accumulation down to 35% of the E_{max} values observed in the wild type receptor (Fig. 3f and Table 1). In contrast, Ala substitution of AsnVII:16 (7.49) one helical turn below, which we previously found to be essential for G_e signaling in the B2AR, had surprisingly almost no effect on the SPinduced signaling through the G_a pathway in the NK1 receptor (Fig. 3g). Similarly, Ala substitution of ThrVII:13 (7.46) and SerIII:15 (3.39) in TM-III located at the top of the water hydrogen bond network had no effect or very little effect on the G_a signaling in the NK1 receptor (Fig. 3, b and e).

Effects of Ala Substitutions on G_s Signaling—As observed for G_q signaling, Ala substitution of the two water-gating microswitch residues TrpVI:13 (6.48) and TyrVII:20 (7.53) as well as Ala substitution of AsnI:18 (1.50) and GluII:10 (2.50) eliminated G_s signaling through the NK1 receptor as measured by SP-induced cAMP accumulation and showed no sign of constitutive G_s signaling either (Fig. 4, *c*, *d*, *h*, and *i*). In contrast, increased basal cAMP production in the absence of agonist was observed not only in GluII:10 but in all of the Ala mutations of the conserved polar residues, except for the mutant forms of SerVII:12 (7.45) and AsnVII:16 (7.49) (Fig. 4 and Table 1). In






FIGURE 3. Functional consequence of Ala substitution on G_q signaling of the conserved polar residues in the NK1 receptor. *a*, structure of the hydrogen bond network in the NK1 receptor model based on $A_{2A}AR$ (PDB code 4EIY) as a template structure. Key side chains are shown as *sticks* and water molecules as *red spheres*. *b*-*h*, agonist (SP)-induced IP₃ production in COS-7 cells transiently transfected with either wild type NK1 (*dotted lines*) or mutant forms of ThrVII:13Ala (7.46) (*b*), GlulI:10Ala (2.50) (*c*), AsnI:18Ala (1.50) (*d*), SerIII:15Ala (3.39) (*e*), SerVII:12Ala (7.45) (*f*), AsnVII:16Ala (7.49) (*g*), TrpVI:13Ala (6.48) (*h*), and TyrVII:20Ala (7.53) (*i*). Cell surface receptor expression measured by ELISA is shown in the column diagram insets in each panel.

particular, the SerIII:15 (3.39) to Ala mutant showed a highly increased constitutive G_s signaling of 37 ± 6% of E_{max} of the wild type receptor corresponding to 24% of its own somewhat increased E_{max} value (Fig. 4). In the case of the AsnI:18 and GluII:10 substitutions, the SP-induced cAMP response was totally eliminated despite the slight but significantly increased basal G_s signaling of the AnsI:18 and GluII:10 mutants. Surprisingly, in view of the lack of effect on G_q signaling, removal of the polar side chain of AsnVII:16 (7.49) by Ala substitution totally eliminated G_s signaling (Figs. 3g and 4g), just as we had observed for Ala substitution of this residue in the B2AR (5). Furthermore, the AsnVII:16 to Ala substitution did not increase basal G_s signaling (Fig. 4).

Effect of Ala Substitutions on β -Arrestin Mobilization—As shown in Fig. 5, the effects of Ala substitution of the residues in the water hydrogen bond network upon β -arrestin mobiliza-

tion were rather similar to the effects observed in G_a signaling (Fig. 3). Thus, as observed in the IP_3 assay, Ala substitution of TrpVI:13 (6.48), TyrVII:20 (7.53), and AsnI:18 (1.50) in all cases eliminated SP-induced β -arrestin mobilization, and Ala substitution of ThrVII:13 (7.46) and SerIII:15 (3.39) located at the top of the hydrogen bond network had almost no effect or induced a slight increase in β -arrestin mobilization. As for IP₃ accumulation assays, a partial inhibition of the β -arrestin response was observed following SerVII:12 (7.46) to Ala mutation (Fig. 5f). In the AsnVII:16 (7.49) to Ala mutant, which selectively inhibited G_s but not G_q , the β -arrestin response was almost similar to that observed for wild type NK1 receptor (Fig. 5g). Interestingly, in the case of GluII:10 (2.50), which was totally unresponsive in both G_{g} and G_{s} signaling, SP responses were evident from β -arrestin mobilization, albeit only \sim 25% of the response observed in the wild type NK1 receptor (Fig. 5c).




FIGURE 4. Functional consequence of Ala substitution on G_s signaling of the conserved polar residues in the NK1 receptor. *a*, structure of the hydrogen bond network in the NK1 receptor model based on A_{2A} AR (PDB code 4EIY) as a template structure. Key side chains are shown as *sticks* and water molecules as *red spheres*. *b*–*h*, agonist (SP)-induced cAMP production in COS-7 cells transiently transfected with either wild type NK1 (*dotted lines*) or mutant forms of ThrVII:13Ala (7.46) (*b*), GlulI:10Ala (2.50) (*c*), AsnI:18Ala (1.50) (*d*), SerIII:15Ala (3.39) (*e*), SerVII:12Ala (7.45) (*f*), AsnVII:16Ala (7.49) (*g*), TrpVI:13Ala (6.48) (*h*), and TyrVII:20Ala (7.53) (*i*).

Effect of Substituting GluII:10 with Gln on NK1 Signaling— To examine the effect of removing the potential negative charge of GluII:10 while retaining the ability to participate in hydrogen bond formation, we introduced Gln at this position. Cell surface expression of the Gln mutant was comparable with the WT receptor as shown in Table 1. Through the G_s pathway the Gln substitution of GluII:10 resulted in a very high constitutive signaling corresponding to almost 40% of $E_{\rm max}$ of the WT receptor, *i.e.* similar to what was observed with the SerIII:15 to Ala mutant (Table 1). The high constitutive G_s signaling could not be further increased by the agonist SP in the GluII:10 to Gln mutant (Table 1). In respect of G_q signaling, sub-nanomolar potency of SP was retained, but the $E_{\rm max}$ value was reduced to 40% of the WT receptor (Table 1), and in respect of β -arrestin mobilization, a 10-fold reduction in potency of SP was observed, although the maximum signaling efficacy resembled the WT receptor (Table 1). It is concluded that GluII:10 very likely in its charged form acts as a negative regulator particularly of G_s signaling because substitution with Gln results in very high constitutive signaling.

Effect of "Reintroduction" of Asp for GluII:10 on NK1 Signaling and Na⁺ Modulation—Mutating GluII:10 (2.50) into aspartic acid, as found in the vast majority of 7TM receptors, increased cell surface expression by ~50% as compared with wild type receptor (Fig. 6a, inset). In contrast to the Ala substitution, the AspII:10 mutant signaled as wild type NK1 through G_q as determined by IP₃ accumulation (Fig. 6a). However, in respect to G_s signaling, the AspII:10 mutant, in contrast to the Ala substitution, displayed no significant constitutive activity in the cAMP assay and had a seriously impaired SP-induced






FIGURE 5. Functional consequence of Ala substitution on β -arrestin2 mobilization of the conserved polar residues in the NK1 receptor. *a*, structure of the hydrogen bond network in the NK1 receptor model based on A_{2A}AR (PDB code 4EIY) as a template structure. Key side chains are shown as *sticks* and water molecules as *red spheres*. *b*-*h*, agonist (SP)-induced β -arrestin2 mobilization in CHOK1 cells transiently transfected with either wild type NK1 (*dotted lines*) or mutant forms of ThrVII:13Ala (7.46) (*b*), GlulI:10Ala (2.50) (*c*), AsnI:18Ala (1.50) (*d*), SerIII:15Ala (3.39) (*e*), SerVII:12Ala (7.45) (*f*), AsnVII:16Ala (7.49) (*g*), TrpVI:13Ala (6.48) (*h*), and TyrVII:20Ala (7.53) (*i*).

cAMP response with a reduction in potency of at least 2 orders of magnitude and not reaching an $E_{\rm max}$ with the highest concentration tested (Fig. 6*b*). In contrast to the GluII:10 to Ala mutant, which did show a clear but diminished β -arrestin response to SP, the GluII:10Asp mutant did not recruit β -arrestin at all upon stimulation with SP (Fig. 6*c*).

The most clear allosteric modulatory effect of Na⁺ in receptors with an Asp in position II:10 is on ligand binding affinity as recently reported for the δ -opioid receptor (27). In the wild type NK1 receptor, no effect of Na⁺ on SP binding was observed in whole cell competition binding using radiolabeled SP in transfected COS-7 cells (Table 2). However, when Asp was reintroduced instead of Glu in position II:10, 300 mM Na⁺ impaired the SP affinity from 0.11 \pm 0.05 nM in its absence to 1.2 \pm 0.5 nM in its presence (Table 2), *i.e.* a negative modulating effect similar to what has been reported for the δ -opioid receptor (27). Ala

substitution of SerIII:15 (3.39), another residue potentially involved in coordinating Na^+ in the water hydrogen bond network, had no effect on the binding of SP in the NK1 receptor, and here no effect on Na^+ was observed (Table 2).

Effect of Introducing Glu at Position II:10 in GPR119, B2AR, and the Ghrelin Receptor—The B2AR, GPR119, and the Ghrelin receptors were chosen because they display variable degrees of constitutive activity, and all carry an Asp in position II:10. Introduction of a Glu residue at this position as in the NK1 receptor decreased the cell surface expression of all three receptors, although they were still expressed at more than 50% of the corresponding WT receptors (Table 3). In the case of GPR119, the effect of the mutation was difficult to interpret as both the constitutive activity and the $E_{\rm max}$ were reduced to ~50% of WT, *i.e.* corresponding to the reduction in expression level. However, the potency of the agonist AR231453 was also reduced, *i.e.*

TABLE 1

G_q, G_s, and β-arrestin signaling of the WT NK1 receptor and mutant forms with Ala substitution in positions Asnl:18 (1.50), Glull:10 (2.50), SerIII:15Ala (3.39), TrpVI:13 (6.48), SerVII:12 (7.45), ThrVII:13 (7.46), AsnVII:16 (7.49), and TyrVII:20 (7.53) and Asp substitution in position GluII:10 (2.50) (2.50)

The constructs were expressed in transiently transfected COS-7 cells (G_g and G_s) and CHOK1 cells (β -arrestin). The E_{max} values are expressed as percentage of the ligand-induced signaling for the WT NK1 receptor. Values are shown \pm S.E. Comparison is between constitutive activity of WT NK1 and the mutant receptors (p < 0.05). ns = not significant.

	IP ₃					cAMP				β-Arrestin2		
Construct	Expression level	п	EC ₅₀ (пм)	E _{max}	n	Constitutive activity	EC ₅₀ (пм)	E _{max}	n	EC ₅₀ (пм)	E _{max}	n
NK1 WT	1	8	0.31 ± 0.11	100	7	1.7 ± 1.4	0.62 ± 0.18	100	5	0.06 ± 0.01	100	8
AsnI:18Ala (1.50)	0.81 ± 0.07	3			3	9.3 ± 6^{a}			4			4
GluII:10Ala (2.50)	0.56 ± 0.05	4			3	10.8 ± 6.7^{b}			4	0.29 ± 0.03	20 ± 3.4	6
GluII:10Gln	1.31 ± 0.09	6	0.72 ± 0.25	38.6 ± 2.5	3	37.7 ± 4.6^{c}			3	0.46 ± 0.25	98.06 ± 11.2	4
GluII:10Asp	1.49 ± 0.09	4	0.35 ± 0.12	85.2 ± 6.3	4	12.0 ± 6.6^{ns}	20.3 ± 9.6	60.9 ± 6.5	4			3
SerIII:15Ala (3.39)	0.85 ± 0.05	3	0.42 ± 0.11	113 ± 5.3	6	37.4 ± 6.1^{c}	1.29 ± 0.35	156 ± 17.7	6	0.07 ± 0.02	157 ± 21.0	10
TrpVI:13Ala (6.48)	0.73 ± 0.05	3			3		0.95 ± 0.43	14.0 ± 4.9	4			4
SerVII:12Ala (7.45)	0.93 ± 0.06	6	0.17 ± 0.06	35.0 ± 6.7	4	4.2 ± 2.1^{ns}			5	0.03 ± 0.007	45.8 ± 4.5	6
ThrVII:13Ala (7.46)	0.84 ± 0.07	4	0.58 ± 0.13	133.4 ± 9.4	4	13.9 ± 4.4^{d}	0.23 ± 0.08	85.5 ± 4.8	4	0.08 ± 0.04	95.2 ± 5.7	6
AsnVII:16Ala (7.49)	0.90 ± 0.06	5	0.35 ± 0.07	76.7 ± 8.1	5				4	0.23 ± 0.07	74.8 ± 8.9	6
TyrVII:20Ala (7.53)	0.78 ± 0.07	3			3				5	0.05 ± 0.02	9.3 ± 2.0	4

 $^{^{}a}_{,} p = 0.0009.$

 $^{d}p = 0.0108.$

 EC_{50} increased from 2.2 to 17 nm (Table 3). In the case of B2AR, introduction of Glu at position II:10 reduced the E_{max} to 17% of WT and the constitutive activity from 9.9 to 2% (Table 3). However, the negative effect on signal transduction was most clearly observed in the ghrelin receptor, where substitution of AspII:10 with Glu totally eliminated both the constitutive signaling and the ghrelin-induced signaling (Table 3).

Discussion

In this study, we tested the unique role of GluII:10 (2.50) of the water hydrogen bond network in the NK1 receptor. Molecular modeling suggests that the side chain of GluII:10 replaces one or more water molecules that normally mediate interactions between the conserved polar residues in inactive conformations of family A GPCRs carrying an Asp residue in position II:10. Consequently, GluII:10 makes direct hydrogen bond interactions to SerIII:15 (3.39) in TM-III and AsnVII:16 (7.49) of the NPXXY motif in TM-VII and thereby conceivably mimics movable water molecules and/or a putative allosteric modulating Na⁺ ion. As observed previously in the B2AR (5), we find here that the water-gating residues of the hydrogen bond network are essential for signal transduction, whereas GluII:10 and its interaction partners are important for fine-tuning the signaling through G_s versus G_q and β -arrestin (Fig. 7).

Is GluII:10 a Tethered Negative Allosteric Regulator in the NK1 Receptor?—The initial hypothesis was that GluII:10 (2.50), by replacing the Na⁺ ion, would function as a tethered negative allosteric modulator and account for the unusual lack of constitutive signaling by the NK1 receptor. The very high maximal constitutive signaling through G_s , observed when GluII:10 was substituted with Gln, supports this notion (Table 1). These data also indicate that it is the deprotonated and charged form of the γ -carboxylic acid group of GluII:10 that acts as an allosteric negative modulator in the NK1 receptor. Introduction of Gln in this position, which has the same size and similar hydrogen bond potential as Glu, increased the constitutive G_s signaling.

Surprisingly, however, we only observed marginal constitutive activity through G_s and no constitutive signaling through G_q when GluII:10 was substituted with Ala (Figs. 3 and 4). One explanation could be that GluII:10 not only functions as an allosteric negative regulator (stabilizing an inactive conformation) but also is essential for not only the SP-induced G_q signaling, as it clearly is (Fig. 3), but is also essential for the ligand-independent constitutive signaling. In other words, GluII:10 is also involved in stabilizing active conformations of the receptor, where it can be replaced by Gln, for example, but not by Ala. In that case, we would not be able to observe any high constitutive signaling in the Ala -substituted receptor because the general importance of GluII:10 for receptor signaling would prevent that. Interestingly, although G-protein signaling was eliminated, SP-induced arrestin signaling was still observed in the GluII:10 to Ala mutant.

The notion that a Glu residue at position II:10 (2.50) can act as an allosteric negative regulator of receptor signaling was further supported by the deleterious effects observed when Glu was introduced instead of AspII:10 in the B2AR, GPR119, and in particular in the ghrelin receptor, where signaling was essentially eliminated. The cell surface expression was somewhat decreased in the AspII:10 to Glu mutant form of the ghrelin receptor; however, we have previously studied a number of ghrelin receptor mutants having similar or even lower expression levels, who nevertheless all signaled efficiently (see Table 2 in Ref. 52).

Differential G_s Versus G_q Signaling through the Water Hydrogen Bond Network—Although most 7TM receptors are known to signal mainly through one G protein pathway, they quite often are able to activate several G proteins (53–55). The NK1 receptor, for example, is best known as a G_q -coupled receptor activating IP₃ and mobilizing calcium. However, substance P in fact activates both G_s and G_q pathways efficiently with similar nanomolar potency (38). Interestingly, the mutational substitutions of the water hydrogen bond network of the NK1 receptor in several aspects affected G_q and G_s signaling differently. Thus, removal of the polar side chain of four out of the six residues of the water hydrogen bond network individually increased the constitutive and ligand-independent G_s signaling without affecting the corresponding basal G_q signaling (Fig. 4). Previ-



 $p^{b} p = 0.0015.$ $p^{c} p < 0.0001.$




FIGURE 6. Functional consequence of Asp substitution of the Glull:10 (2.50) residue in the NK1 receptor. a-c, agonist (SP)-induced IP₃ (a), cAMP (b), or β -Arrestin2 (c) mobilization in COS-7 cells (IP₃ and cAMP) or CHOK1 cells (β -arrestin2) transiently transfected with either wild type NK1 (*dotted lines*) or mutant Glull:10Ala/Asp. Cell surface receptor expression measured by ELISA is shown in the column diagram *inset* in a.

ously, we have observed a similar phenomenon in the B2AR, where Ala substitution of AsnI:18, AspII:10, and SerVII:13, which jointly are coordinating the mobile water molecules in this receptor, also increased the basal, ligand-independent G_s signaling (5).

The agonist-induced G_s versus G_q signaling was also differentially affected by mutational substitutions of the hydrogen bond network. Most notably, Ala substitution of AsnVII:16 (7.49) of the NPXXY motif selectively eliminated G_s signaling with no effect on the G_q pathway. The SerVII:12 (7.45) to Ala mutant located one helical turn above in TM-VII had a similar

phenotype but with a somewhat impaired G_q response (Figs. 3 and 4). Similarly, in the B2AR, Ala substitution of the corresponding two residues both abolished agonist-induced receptor activation through G_s (5). Interestingly, molecular modeling studies of the G_s-coupled thyrotropin receptor suggested that AsnVII:16 (7.49) acted as an on/off switch in receptor activation, which was confirmed in functional studies as the Asn-VII:16 to Ala mutant form could not be activated by thyrotropin, although it bound the agonist with wild type affinity and displayed a normal high constitutive basal G_s signaling (56). In the cholecystokinin receptor, the AsnVII:16 (7.49) residue has been demonstrated to be essential for G_q signaling (57). Apparently, the interface between TM-II, TM-III, and TM-VII is particularly important for G_{s} versus G_{q} signaling. Previously, we identified another residue located at this interface but more toward the extracellular side between TM-II and TM-III, i.e. PheIII:07 (3.31), which upon substitution to Ser also selectively uncoupled the NK1 receptor from the G_s pathway while leaving G_{q} signaling intact (38).

 β -Arrestin Versus G Protein Signaling through the Water Hydrogen Bond Network-Both ligands and mutations have been shown to be able to stabilize distinct conformations leading to biased receptor signaling within specific GPCRs (4, 38, 58-62). As shown in Fig. 7, we find that mutations of GluII:10 and AsnVII:16, which according to the molecular modeling in the NK1 receptor, are interacting directly with each other, result in biased signaling, i.e. where the three signaling pathways G_s , G_q , and β -arrestin mobilization are differentially affected. Thus, in the AsnVII:16 to Ala mutant, the G_s signaling was selectively eliminated, although both G_q signaling and β -arrestin mobilization were similar to wild type NK1. In contrast, in the GluII:10 (2.50) to Ala mutant, both SP-induced G_a and G_s signaling were totally eliminated, although the SP-induced recruitment of β -arrestin was rather well preserved in particular when taking into account the somewhat reduced cell surface expression (Fig. 5). Thus, removal of the acidic side chain of GluII:10 by Ala substitution converted the NK1 receptor into a clean β -arrestin-biased receptor. However, when GluII:10 instead was substituted with the shorter acidic Asp residue, as found in most other receptors, β -arrestin mobilization was totally eliminated and G_s signaling was seriously impaired, although G_q signaling was similar to wild type NK1 (Fig. 6). This underlines the crucial importance of the water hydrogen bond network for fine-tuning the signaling of the NK1 receptor through different signal transduction pathways (Fig. 7).

Interestingly, an interaction between AspII:10 (2.50) and AsnVII:16 (7.49) of the NPXXY motif in TM-VII was proposed early on in several receptors based on observations that paired swap of these two residues could restore receptor signaling, compared with the detrimental effects of each of the single mutations (50, 63–65). Furthermore, rearrangements in this region during activation have also been shown for rhodopsin using radiolytic protein footprinting (66).

Water-gating Residues of the Hydrogen Bond Network Are Essential for Signaling in General—Three residues appeared to be essential for all three signaling pathways, G_q , G_s , and β -arrestin mobilization; the two water-gating micro-switch resi-

TABLE 2

Ligand binding properties of SP to WT NK1 receptor and substitutions in position Glull:10 (2.50) and SerIII:15 (3.39) in the NK1 receptor using ¹²⁵I-labeled SP as a radioligand

The constructs were expressed in transiently transfected COS-7 cells. Values are shown \pm S.E.

		K_d (nM)						
Construct	п	0 mм NaCl	50 mм NaCl	100 mм NaCl	200 mм NaCl	300 mм NaCl		
WT NK1	5	0.125 ± 0.06	0.116 ± 0.03	0.187 ± 0.09	0.314 ± 0.16	0.253 ± 0.08		
GluII:10A (2.50)	5	0.657 ± 0.28	0.520 ± 0.13	0.778 ± 0.11	1.45 ± 0.43	3.18 ± 2.09		
GluII:10D	5	0.114 ± 0.04	0.128 ± 0.02	0.204 ± 0.06	0.290 ± 0.07	1.20 ± 0.54		
SerIII:15A (3.39)	4	0.172 ± 0.04	0.469 ± 0.32	0.284 ± 0.13	0.310 ± 0.10	0.446 ± 0.09		

TABLE 3

G_a or G_s signaling of the WT GHSR, B2AR, and GPPR119 and the AspII:10Glu mutant variant of these receptors

The constructs were expressed in transiently transfected COS-7 cells. The constitutive and ghrelin-induced G_q signaling was determined for the ghrelin receptor, whereas signaling through the G_s signaling pathway was determined for B2AR (pindolol) and GPR119 (AR-231453). The E_{max} values are expressed as percentage of the ligand-induced signaling for the WT receptors. Values are shown \pm S.E. CA means constitutive activity.

Construct	Expression level	п	CA	EC ₅₀ (nм) (ligand)	$E_{\rm max}$	п
GHSR 1a WT	1 ± 0.02	3	43.4 ± 2.06	0,36 ± 0.27 (Ghrelin)	100	3
AspII:10Glu	0.60 ± 0.06	3				3
B2ÂR WT	1 ± 0.03	5	9.9 ± 2.55	2.97 ± 1.09 (Pindolol)	100	6
AspII:10Glu	0.68 ± 0.06	5	2 ± 1.92	5.68 ± 2.90	16.6 ± 5.35	5
GPR119 WT	1 ± 0.09	5	43.6 ± 3.43	2.22 ± 0.34 (AR-231453)	100	5
AspII:10Glu	0.51 ± 0.11	5	27.5 ± 5.3	17.0 ± 5.01	56 ± 5.01	5




FIGURE 7. Residues of the water hydrogen bond network of the NK1 receptor identified to be either essential for overall signal transduction or for the fine-tuning and bias of signaling through the three different signaling pathways: $G_{s'}$, $G_{q'}$ and β -arrestin. Three residues were by Ala substitutions identified to be essential for all three signal transduction pathways as follows: the water-gating TrpVI:13 (6.48) of the CWXP motif and the TyrVII:20 (7.53) of the NPXXY motif as well as the ultra-highly conserved TM-VII kink-stabilizing AsnI:18 (1.50). Mutations of GlulI:10 (2.50) and the two residues SerIII:15 (3.39) and AsnVII:16 (7.49), to which GluII:10 according to the molecular models makes direct hydrogen bond interactions, result in receptor mutants with biased signaling as follows: β -arrestin only (GluII:10 to Ala), G_q only (GluII:10 to Asp), high constitutive G_s signaling (GluII:10 to Gln), and G_q plus β -arrestin but not G_s (AsNVII:16 to Ala). Ala substitution of SerIII:15 selectively increases G_s signaling from zero to ~40% of E_{max} .

dues, TrpVI:13 (6.48) and TyrVII:20 (7.53), and the totally conserved AsnI:18 (1.50) (Fig. 7).

Originally, we demonstrated by molecular dynamics simulations based on the high resolution structures of rhodopsin and B2AR that most of the water molecules of the network are highly mobile and that the entry and exit of these waters in and out of the network is gated by micro-switch residues, *i.e.* toward the ligand-binding pocket by TrpVI:13 and toward the intracellular cytosol by the rotary micro-switch TyrVII:20 (see central vignette in Figs. 3–5) (5). Structures of active receptor conformations subsequently demonstrated that the "water volume" of the hydrogen bond network changes considerably in the transition between inactive and active conformations in which most of the water molecules are "squeezed" out (16, 27). Thus, the movement of water molecules in and out of the network and the gating of these must be essential for receptor function (5). Accordingly, in this study of the NK1 receptor, we find that both of the "water-gating" residues, TrpVI:13 and TyrVII:20, are essential for all three signaling pathways tested, just as we found they were essential for the G_s signaling in the B2AR (5). TrpVI:13 has been extensively studied and determined to be essential for receptor activation in multiple 7TM receptors (46). The rotameric micro-switch, TyrVII:20, in its inward rotameric form stabilizes the outward tilt of TM-VI (2), which opens a pocket between the helices allowing for G protein binding (29, 67–70).

AsnI:18 (1.50), which in the inactive receptor conformation makes a helix kink-stabilizing hydrogen bond to the backbone carbonyl of the residue in position VII:13 (7.46) exposed by the highly conserved ProVII:17 (7.50) of the NPXXY motif, is the only residue that is totally conserved throughout the entire large rhodopsin-like family A of 7TM receptors (42). In the NK1 receptor the AsnI:18 (1.50) to Ala mutant abolished all receptor signaling. The extraordinary conservation of this residue in 7TM receptors would suggests that it is essential in receptor signaling in general. However, in the B2AR we found that the corresponding AsnI:18 to Ala substitution surprisingly had no effect on the agonist-induced G_s signaling, and in fact it increased the constitutive activity (5).

Conclusion—Based on the x-ray structures, molecular dynamics simulations, and mutational analysis, we have previously proposed that the extended water hydrogen bond network between TM-I–III, -VI, and -VII constitutes an allosteric interface essential for stabilizing different active and inactive helical constellations during receptor activation (5). Here, we confirm that the water-gating micro-switch residues TrpVI:13 (6.48) of the CWXP motif and TyrVII:20 (7.53) of the NPXXY motif are essential for all signaling also in the NK1 receptor. Importantly, we identify the interaction between the unique



Glu in position II:10 (2.50), SerIII:15 (3.39), and AsnVII:16 (7.49) of the NPXXY motif in TM-VII as a key point for determining G_s versus G_q signaling as well as β -arrestin mobilization. Specifically, the interface between TM-II, -III, and -VII appears to be particularly important for G_s signaling, which could potentially be used in future drug discovery efforts. For example, it may be possible to generate agonists with an appropriate signaling bias ensuring proper balance in efficacy through the G_s and the G_q pathways as recently described for the long chain fatty acid receptor GPR40 to obtain appropriate *in vivo* incretin-releasing efficacy (49).


Author Contributions—L. V. H., T. M. F., and T. W. S. conceived the study and wrote the manuscript. L. V. H., J. M., and N. D. H. performed and analyzed the experiments. All comparative homology modeling was conducted and analyzed by T. M. F. All authors reviewed the results and approved the final version of the manuscript.

Acknowledgments—The Novo Nordisk Foundation Center for Basic Metabolic Research is based on an unconditional grant from the Novo Nordisk Foundation to the Faculty of Health Sciences at University of Copenhagen.

References

- Rosenbaum, D. M., Rasmussen, S. G., and Kobilka, B. K. (2009) The structure and function of G-protein-coupled receptors. *Nature* 459, 356–363
- Nygaard, R., Frimurer, T. M., Holst, B., Rosenkilde, M. M., and Schwartz, T. W. (2009) Ligand binding and micro-switches in 7TM receptor structures. *Trends Pharmacol. Sci.* 30, 249–259
- 3. Katritch, V., Cherezov, V., and Stevens, R. C. (2013) Structure-function of the G protein-coupled receptor superfamily. *Annu. Rev. Pharmacol. Toxicol.* **53**, 531–556
- 4. Wisler, J. W., Xiao, K., Thomsen, A. R., and Lefkowitz, R. J. (2014) Recent developments in biased agonism. *Curr. Opin. Cell Biol.* **27**, 18–24
- Nygaard, R., Valentin-Hansen, L., Mokrosinski, J., Frimurer, T. M., and Schwartz, T. W. (2010) Conserved water-mediated hydrogen bond network between TM-I, -II, -VI, and -VII in 7TM receptor activation. *J. Biol. Chem.* 285, 19625–19636
- Stevens, R. C., Cherezov, V., Katritch, V., Abagyan, R., Kuhn, P., Rosen, H., and Wüthrich, K. (2013) The GPCR network: a large-scale collaboration to determine human GPCR structure and function. *Nat. Rev. Drug Discov.* 12, 25–34
- Srivastava, A., Yano, J., Hirozane, Y., Kefala, G., Gruswitz, F., Snell, G., Lane, W., Ivetac, A., Aertgeerts, K., Nguyen, J., Jennings, A., and Okada, K. (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. *Nature* **513**, 124–127
- Zhang, K., Zhang, J., Gao, Z. G., Zhang, D., Zhu, L., Han, G. W., Moss, S. M., Paoletta, S., Kiselev, E., Lu, W., Fenalti, G., Zhang, W., Müller, C. E., Yang, H., Jiang, H., *et al.* (2014) Structure of the human P2Y12 receptor in complex with an antithrombotic drug. *Nature* 509, 115–118
- Tan, Q., Zhu, Y., Li, J., Chen, Z., Han, G. W., Kufareva, I., Li, T., Ma, L., Fenalti, G., Li, J., Zhang, W., Xie, X., Yang, H., Jiang, H., Cherezov, V., *et al.* (2013) Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. *Science* 341, 1387–1390
- Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G., Thian, F. S., Kobilka, T. S., Choi, H. J., Kuhn, P., Weis, W. I., Kobilka, B. K., and Stevens, R. C. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. *Science* 318, 1258–1265
- Chien, E. Y., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., Newman, A. H., Javitch, J. A., Cherezov, V., and Stevens, R. C. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. *Science* **330**, 1091–1095

- 12. Granier, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I., and Kobilka, B. K. (2012) Structure of the δ -opioid receptor bound to naltrindole. *Nature* **485**, 400–404
- Haga, K., Kruse, A. C., Asada, H., Yurugi-Kobayashi, T., Shiroishi, M., Zhang, C., Weis, W. I., Okada, T., Kobilka, B. K., Haga, T., and Kobayashi, T. (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. *Nature* 482, 547–551
- Hanson, M. A., Roth, C. B., Jo, E., Griffith, M. T., Scott, F. L., Reinhart, G., Desale, H., Clemons, B., Cahalan, S. M., Schuerer, S. C., Sanna, M. G., Han, G. W., Kuhn, P., Rosen, H., and Stevens, R. C. (2012) Crystal structure of a lipid G protein-coupled receptor. *Science* 335, 851–855
- Kruse, A. C., Hu, J., Pan, A. C., Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobilka, B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. *Nature* 482, 552–556
- Liu, W., Chun, E., Thompson, A. A., Chubukov, P., Xu, F., Katritch, V., Han, G. W., Roth, C. B., Heitman, L. H., IJzerman, A. P., Cherezov, V., and Stevens, R. C. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. *Science* 337, 232–236
- Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., and Granier, S. (2012) Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. *Nature* 485, 321–326
- Ruprecht, J. J., Mielke, T., Vogel, R., Villa, C., and Schertler, G. F. (2004) Electron crystallography reveals the structure of metarhodopsin I. *EMBO J.* 23, 3609–3620
- Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G. W., Kobayashi, T., Stevens, R. C., and Iwata, S. (2011) Structure of the human histamine H1 receptor complex with doxepin. *Nature* 475, 65–70
- 20. Thompson, A. A., Liu, W., Chun, E., Katritch, V., Wu, H., Vardy, E., Huang, X. P., Trapella, C., Guerrini, R., Calo, G., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. *Nature* 485, 395–399
- Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X. P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., Liu, W., Xu, H. E., Cherezov, V., Roth, B. L., and Stevens, R. C. (2013) Structural features for functional selectivity at serotonin receptors. *Science* 340, 615–619
- 22. Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G. W., Liu, W., Huang, X. P., Vardy, E., McCorvy, J. D., Gao, X., Zhou, X. E., Melcher, K., Zhang, C., *et al.* (2013) Structural basis for molecular recognition at serotonin receptors. *Science* **340**, 610–614
- Warne, T., Serrano-Vega, M. J., Baker, J. G., Moukhametzianov, R., Edwards, P. C., Henderson, R., Leslie, A. G., Tate, C. G., and Schertler, G. F. (2008) Structure of a β1-adrenergic G-protein-coupled receptor. *Nature* 454, 486–491
- Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V., and Stevens, R. C. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. *Science* 330, 1066–1071
- Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the human κ-opioid receptor in complex with JDTic. *Nature* 485, 327–332
- Zhang, C., Srinivasan, Y., Arlow, D. H., Fung, J. J., Palmer, D., Zheng, Y., Green, H. F., Pandey, A., Dror, R. O., Shaw, D. E., Weis, W. I., Coughlin, S. R., and Kobilka, B. K. (2012) High-resolution crystal structure of human protease-activated receptor 1. *Nature* 492, 387–392
- Fenalti, G., Giguere, P. M., Katritch, V., Huang, X. P., Thompson, A. A., Cherezov, V., Roth, B. L., and Stevens, R. C. (2014) Molecular control of δ-opioid receptor signalling. *Nature* 506, 191–196
- Gutiérrez-de-Terán, H., Massink, A., Rodríguez, D., Liu, W., Han, G. W., Joseph, J. S., Katritch, I., Heitman, L. H., Xia, L., Ijzerman, A. P., Cherezov, V., Katritch, V., and Stevens, R. C. (2013) The role of a sodium ion binding site in the allosteric modulation of the A2A adenosine G protein-coupled receptor. *Structure* 21, 2175–2185



- Rasmussen, S. G., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T., Lyons, J. A., Caffrey, M., Gellman, S. H., *et al.* (2011) Crystal structure of the β2 adrenergic receptor-G_s protein complex. *Nature* 477, 549–555
- Xu, F., Wu, H., Katritch, V., Han, G. W., Jacobson, K. A., Gao, Z. G., Cherezov, V., and Stevens, R. C. (2011) Structure of an agonist-bound human A2A adenosine receptor. *Science* 332, 322–327
- Costa, T., Lang, J., Gless, C., and Herz, A. (1990) Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. *Mol. Pharmacol.* 37, 383–394
- Gao, Z. G., and Ijzerman, A. P. (2000) Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. *Biochem. Pharmacol.* 60, 669–676
- Horstman, D. A., Brandon, S., Wilson, A. L., Guyer, C. A., Cragoe, E. J., Jr., and Limbird, L. E. (1990) An aspartate conserved among G-protein receptors confers allosteric regulation of α2-adrenergic receptors by sodium. *J. Biol. Chem.* 265, 21590–21595
- Selent, J., Sanz, F., Pastor, M., and De Fabritiis, G. (2010) Induced effects of sodium ions on dopaminergic G-protein coupled receptors. *PLoS Comput. Biol.* 6, e1000884
- 35. Wilson, M. H., Highfield, H. A., and Limbird, L. E. (2001) The role of a conserved inter-trans-membrane domain interface in regulating α (2a)-adrenergic receptor conformational stability and cell-surface turnover. *Mol. Pharmacol.* **59**, 929–938
- Schwartz, T. W., and Holst, B. (2007) Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? *Trends Pharmacol. Sci.* 28, 366–373
- Katritch, V., Fenalti, G., Abola, E. E., Roth, B. L., Cherezov, V., and Stevens, R. C. (2014) Allosteric sodium in class A GPCR signaling. *Trends Biochem. Sci.* 39, 233–244
- Holst, B., Hastrup, H., Raffetseder, U., Martini, L., and Schwartz, T. W. (2001) Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. *J. Biol. Chem.* 276, 19793–19799
- Martini, L., Hastrup, H., Holst, B., Fraile-Ramos, A., Marsh, M., and Schwartz, T. W. (2002) NK1 receptor fused to β-arrestin displays a singlecomponent, high-affinity molecular phenotype. *Mol. Pharmacol.* 62, 30–37
- Quartara, L., and Maggi, C. A. (1997) The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. *Neuropeptides* 31, 537–563
- Schwartz, T. W., Frimurer, T. M., Holst, B., Rosenkilde, M. M., and Elling, C. E. (2006) Molecular mechanism of 7TM receptor activation–a global toggle switch model. *Annu. Rev. Pharmacol. Toxicol.* 46, 481–519
- Mirzadegan, T., Benkö, G., Filipek, S., and Palczewski, K. (2003) Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. *Biochemistry* 42, 2759–2767
- Gether, U., Johansen, T. E., Snider, R. M., Lowe, J. A., 3rd, Nakanishi, S., and Schwartz, T. W. (1993) Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. *Nature* 362, 345–348
- 44. Gether, U., Yokota, Y., Emonds-Alt, X., Brelière, J. C., Lowe, J. A., 3rd, Snider, R. M., Nakanishi, S., and Schwartz, T. W. (1993) Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 6194–6198
- Holst, B., Zoffmann, S., Elling, C. E., Hjorth, S. A., and Schwartz, T. W. (1998) Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. *Mol. Pharmacol.* 53, 166–175
- Holst, B., Nygaard, R., Valentin-Hansen, L., Bach, A., Engelstoft, M. S., Petersen, P. S., Frimurer, T. M., and Schwartz, T. W. (2010) A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seventrans-membrane receptors. *J. Biol. Chem.* 285, 3973–3985
- 47. Nielsen, S. M., Elling, C. E., and Schwartz, T. W. (1998) Split-receptors in the tachykinin neurokinin-1 system–mutational analysis of intracellular

loop 3. Eur. J. Biochem. 251, 217-226

- 48. Miller-Gallacher, J. L., Nehmé, R., Warne, T., Edwards, P. C., Schertler, G. F., Leslie, A. G., and Tate, C. G. (2014) The 2.1 A resolution structure of cyanopindolol-bound β 1-adrenoceptor identifies an intramembrane Na⁺ ion that stabilises the ligand-free receptor 2. *PLoS One* **9**, e92727
- 49. Hauge, M., Vestmar, M. A., Husted, A. S., Ekberg, J. P., Wright, M. J., Di Salvo, J., Weinglass, A. B., Engelstoft, M. S., Madsen, A. N., Lückmann, M., Miller, M. W., Trujillo, M. E., Frimurer, T. M., Holst, B., Howard, A. D., and Schwartz, T. W. (2015) GPR40 (FFAR1)– combined Gs and Gq signaling *in vitro* is associated with robust incretin secretagogue action *ex vivo* and *in vivo*. *Mol. Metab.* **4**, 3–14
- Zhou, W., Flanagan, C., Ballesteros, J. A., Konvicka, K., Davidson, J. S., Weinstein, H., Millar, R. P., and Sealfon, S. C. (1994) A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. *Mol. Pharmacol.* 45, 165–170
- Jaakola, V. P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y., Lane, J. R., Ijzerman, A. P., and Stevens, R. C. (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. *Science* **322**, 1211–1217
- Sivertsen, B., Lang, M., Frimurer, T. M., Holliday, N. D., Bach, A., Els, S., Engelstoft, M. S., Petersen, P. S., Madsen, A. N., Schwartz, T. W., Beck-Sickinger, A. G., and Holst, B. (2011) Unique interaction pattern for a functionally biased ghrelin receptor agonist. *J. Biol. Chem.* 286, 20845–20860
- Jin, L. Q., Wang, H. Y., and Friedman, E. (2001) Stimulated D(1) dopamine receptors couple to multiple Gα proteins in different brain regions. J. Neurochem. 78, 981–990
- 54. Kilts, J. D., Gerhardt, M. A., Richardson, M. D., Sreeram, G., Mackensen, G. B., Grocott, H. P., White, W. D., Davis, R. D., Newman, M. F., Reves, J. G., Schwinn, D. A., and Kwatra, M. M. (2000) β(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i). *Circ. Res.* 87, 705–709
- 55. Laugwitz, K. L., Allgeier, A., Offermanns, S., Spicher, K., Van Sande, J., Dumont, J. E., and Schultz, G. (1996) The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 116–120
- Govaerts, C., Lefort, A., Costagliola, S., Wodak, S. J., Ballesteros, J. A., Van Sande, J., Pardo, L., and Vassart, G. (2001) A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor. *J. Biol. Chem.* 276, 22991–22999
- 57. Galés, C., Kowalski-Chauvel, A., Dufour, M. N., Seva, C., Moroder, L., Pradayrol, L., Vaysse, N., Fourmy, D., and Silvente-Poirot, S. (2000) Mutation of Asn-391 within the conserved NPXXY motif of the cholecystokinin B receptor abolishes G_q protein activation without affecting its association with the receptor. *J. Biol. Chem.* **275**, 17321–17327
- Webb, D. R., Handel, T. M., Kretz-Rommel, A., and Stevens, R. C. (2013) Opportunities for functional selectivity in GPCR antibodies. *Biochem. Pharmacol.* 85, 147–152
- Luttrell, L. M. (2014) Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. *Mol. Endocrinol.* 28, 281–294
- Shukla, A. K., Violin, J. D., Whalen, E. J., Gesty-Palmer, D., Shenoy, S. K., and Lefkowitz, R. J. (2008) Distinct conformational changes in β-arrestin report biased agonism at seven-trans-membrane receptors. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 9988–9993
- Wei, H., Ahn, S., Shenoy, S. K., Karnik, S. S., Hunyady, L., Luttrell, L. M., and Lefkowitz, R. J. (2003) Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. *Proc. Natl. Acad. Sci. U.S.A.* 100, 10782–10787
- 62. Steen, A., Thiele, S., Guo, D., Hansen, L. S., Frimurer, T. M., and Rosenkilde, M. M. (2013) Biased and constitutive signaling in the CC-chemokine receptor CCR5 by manipulating the interface between trans-membrane helices 6 and 7. *J. Biol. Chem.* **288**, 12511–12521
- Urizar, E., Claeysen, S., Deupí, X., Govaerts, C., Costagliola, S., Vassart, G., and Pardo, L. (2005) An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor. *J. Biol. Chem.* 280, 17135–17141
- 64. Sealfon, S. C., Chi, L., Ebersole, B. J., Rodic, V., Zhang, D., Ballesteros, J. A., and Weinstein, H. (1995) Related contribution of specific helix 2 and 7



residues to conformational activation of the serotonin 5-HT2A receptor. *J. Biol. Chem.* **270,** 16683–16688

- 65. Nikiforovich, G. V., Zhang, M., Yang, Q., Jagadeesh, G., Chen, H. C., Hunyady, L., Marshall, G. R., and Catt, K. J. (2006) Interactions between conserved residues in trans-membrane helices 2 and 7 during angiotensin AT1 receptor activation. *Chem. Biol. Drug Des.* **68**, 239–249
- Angel, T. E., Gupta, S., Jastrzebska, B., Palczewski, K., and Chance, M. R. (2009) Structural waters define a functional channel mediating activation of the GPCR, rhodopsin. *Proc. Natl. Acad. Sci. U.S.A.* 106, 14367–14372
- Choe, H. W., Kim, Y. J., Park, J. H., Morizumi, T., Pai, E. F., Krauss, N., Hofmann, K. P., Scheerer, P., and Ernst, O. P. (2011) Crystal structure of

metarhodopsin II. Nature 471, 651-655

- Park, J. H., Scheerer, P., Hofmann, K. P., Choe, H. W., and Ernst, O. P. (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. *Nature* 454, 183–187
- Rasmussen, S. G., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F. S., Kobilka, T. S., Schnapp, A., Konetzki, I., Sunahara, R. K., Gellman, S. H., Pautsch, A., *et al.* (2011) Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. *Nature* 469, 175–180
- Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauss, N., Choe, H. W., Hofmann, K. P., and Ernst, O. P. (2008) Crystal structure of opsin in its G-protein-interacting conformation. *Nature* 455, 497–502

